These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31354382)

  • 1. How Effective Are Noninvasive Tests for Diagnosing Malignant Peripheral Nerve Sheath Tumors in Patients with Neurofibromatosis Type 1? Diagnosing MPNST in NF1 Patients.
    Schwabe M; Spiridonov S; Yanik EL; Jennings JW; Hillen T; Ponisio M; McDonald DJ; Dehdashti F; Cipriano CA
    Sarcoma; 2019; 2019():4627521. PubMed ID: 31354382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
    Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
    Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
    Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
    Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Ristow I; Madesta F; Well L; Shenas F; Wright F; Molwitz I; Farschtschi S; Bannas P; Adam G; Mautner VF; Werner R; Salamon J
    Neuro Oncol; 2022 Oct; 24(10):1790-1798. PubMed ID: 35426432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.
    Broski SM; Johnson GB; Howe BM; Nathan MA; Wenger DE; Spinner RJ; Amrami KK
    Skeletal Radiol; 2016 Aug; 45(8):1097-105. PubMed ID: 27115884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1.
    Liu J; Huang JN; Wang MH; Ni ZY; Jiang WH; Chung M; Wei CJ; Wang ZC
    Front Oncol; 2022; 12():898971. PubMed ID: 35677169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI.
    Ristow I; Kaul MG; Stark M; Zapf A; Riedel C; Lenz A; Mautner VF; Farschtschi S; Apostolova I; Adam G; Bannas P; Salamon J; Well L
    Neurooncol Adv; 2024; 6(1):vdae021. PubMed ID: 38468867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.
    Uthoff J; De Stefano FA; Panzer K; Darbro BW; Sato TS; Khanna R; Quelle DE; Meyerholz DK; Weimer J; Sieren JC
    J Neuroradiol; 2019 May; 46(3):179-185. PubMed ID: 29958847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Quality of Magnetic Resonance Imaging Interpretation for Peripheral Nerve Sheath Tumors: Can Malignancy Be Determined?
    Karsy M; Guan J; Ravindra VM; Stilwill S; Mahan MA
    J Neurol Surg A Cent Eur Neurosurg; 2016 Nov; 77(6):495-504. PubMed ID: 27276118
    [No Abstract]   [Full Text] [Related]  

  • 16. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1.
    Raad RA; Lala S; Allen JC; Babb J; Mitchell CW; Franceschi AM; Yohay K; Friedman KP
    World J Nucl Med; 2018; 17(4):241-248. PubMed ID: 30505221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors.
    Koike H; Nishida Y; Ito S; Shimoyama Y; Ikuta K; Urakawa H; Sakai T; Shimizu K; Ito K; Imagama S
    World Neurosurg; 2022 Jan; 157():e207-e214. PubMed ID: 34624521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
    Benz MR; Czernin J; Dry SM; Tap WD; Allen-Auerbach MS; Elashoff D; Phelps ME; Weber WA; Eilber FC
    Cancer; 2010 Jan; 116(2):451-8. PubMed ID: 19924789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of magnetic resonance imaging in the diagnostic evaluation of malignant peripheral nerve sheath tumors.
    Chhabra A; Soldatos T; Durand DJ; Carrino JA; McCarthy EF; Belzberg AJ
    Indian J Cancer; 2011; 48(3):328-34. PubMed ID: 21921333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.